THE COMPLETE #OncoAlertColloquium ?? ON DEMAND, JUST CLICK & WATCH ACCESS HERE ?? ?? https://buff.ly/5kZb0x2 ???? NO REGISTRATION NEEDED?? The Breakdown of the 2024 colloquium DAY 1 (GU Oncology) DAY 2 (Thoracic Oncology) DAY 3 (Breast Cancer) DAY 4 (GI Oncology) Day 5 (Gynecological Oncology) Day 6 (Special Sessions) Day 7 (How I Treat Cancer When I dont have access to the Treatment) Our Faculty Hope Rugo ???? Erika Hamilton, MD ???? Silke Gillessen ???? Sharlene Gill MD, MPH, MBA, FASCO, FRCP(C) ???? Allison Betof Warner ???? Christina Fotopoulou ???? Nicolò Bizzarri ???? GILBERTO de lima LOPES Junior ???? Icro Meattini ???? Maryam Lustberg ???? Stephanie Graff, MD, FACP, FASCO ???? Cathy Eng ???? Jarushka Naidoo ???? Matteo Lambertini ???? Umberto Malapelle ???? Ane Gerda Zahl Eriksson ???? Raúl Córdoba Mascu?ano ???? Petros Grivas ???? Allison Rosen, MS ???? Roberto Salgado ???? Professor Declan Murphy ???? Renu Eapen???? Wenxin (Vincent) Xu ???? Fatima Cardoso ???? Henning Willers, MD, FASTRO ???? Benedikt Westphalen Westphalen ???? Evandro de Azambuja???? Kevin Punie ???? Enrique Soto ???? Nina Sanford ???? Charu Aggarwal ???? Bryan Lewis ???? Melissa Kah Poh Loh, MD, MS, FACCC, FASCO ???? Florence (Katie) Keane ???? Jon Trent ???? Fadi Haddad???? Al-Ola Abdallah ???? José Fernando Prado Moura ???? Dra. María Natalia Gandur Quiroga ???? Rogelio Velasco Jr., MD ???? Aleksandra Strojna ???? Annamaria Ferrero???? Alejandra Martinez???????? Isabelle Ray-Coquard ???? Maaike Oonk???? Cyrus Chargari ???? Kim Hulscher???? Elisa Agostinetto Biagio Ricciuti
OncoAlert
医疗机构
San Antonio，Texas 10,957 位关注者
OncoAlert is one of the most influential networks in oncology, amplifying voices & promoting collegial collaborations
关于我们
OncoAlert, an international network of oncology stakeholders, with a faculty of over 150 influential colleagues (Med/Rad/Surg oncologists, nurses, scientists & patients advocates). Since its establishment in March 2019, the network has had strong social media presence on X/Twitter, LinkedIn, Instagram, YouTube, and Facebook and it reaches over 34,200 colleagues on X alone. The network's mandates include education, patient advocacy (10% of our faculty are Patient Advocates), and global oncology equality. OncoAlert is a leading presence at major oncology congresses and produces a weekly newsletter reaching 5,000 colleagues with a 55-65% opening rate among cancer stakeholders 40% in the US, 30% in Western Europe and 30% spread throughout the world. Our multifaceted approach fosters direct engagement and dissemination of current oncology information, making OncoAlert one of the most influential networks in the field, amplifying voices and promoting collaboration among oncology professionals worldwide.
- 网站
-
https://WWW.OncoAlert360.com
OncoAlert的外部链接
- 所属行业
- 医疗机构
- 规模
- 2-10 人
- 总部
- San Antonio，Texas
- 类型
- 非营利机构
- 创立
- 2019
- 领域
- Medical Oncology、Clinical Oncology、Radiation Oncology、Surgical Oncology、Medical Education、Patient advocacy和LMIC's
地点
OncoAlert员工
动态
-
Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer #NSCLC ?? : Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial https://buff.ly/J7VndDU This phase I/II study evaluating selpercatinib in RET fusion-positive non–small cell #Lungancer (NSCLC) saw Final results with durable efficacy, an objective response rate (ORR) of 62% in patients who had prior platinum-based chemotherapy and 83% in treatment-na?ve patients. The duration of response (DoR) was 31.6 months and 20.3 months, respectively, and progression-free survival (PFS) was 26.2 months for pretreated and 22.0 months for treatment-na?ve patients. At 3 years, 57% of pretreated and 66% of treatment-na?ve patients were alive. Selpercatinib also demonstrated an 85% ORR in patients with CNS metastases. Oliver Gautschi Keunchil Park Ben Solomon ?Herbert Loong, MBBS FRCP FASCO Filippo de Braud Geoff Oxnard Bente Frimodt-M?ller Alexander Drilon
-
-
The study highlights the effectiveness of these ablative methods and encourages multidisciplinary approaches to individualized treatment decisions, suggesting further randomized trials to assess long-term outcomes. hashtag #kidneyCancer
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis out on Lancet Oncology https://lnkd.in/d-6UTEwe Systematic review and meta-analysis compared the clinical efficacy and safety of four non-invasive and minimally invasive ablative treatments—stereotactic body radiotherapy (SBRT)??, radiofrequency ablation, microwave ablation, and cryoablation—in patients with localized renal cell carcinoma. Data from 133 studies involving 8910 patients were analyzed to determine local control rates at 1, 2, and 5 years post-treatment. SBRT had the highest local control rates at 5 years (95%), followed by radiofrequency ablation (92%), cryoablation (90%), and microwave ablation (86%). Adverse events were low across all treatments, with grade 3–4 adverse events ranging from 1% to 3%. The study highlights the effectiveness of these ablative methods and encourages multidisciplinary approaches to individualized treatment decisions, suggesting further randomized trials to assess long-term outcomes. #kidneyCancer David Chen Christopher Wallis Charles B. Simone, MMS, M.D. Michael Lock
-
-
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer #SCLC : the phase I/II LUPER study out on JTO https://buff.ly/iJLYfNv The LUPER trial assessed the efficacy and safety of lurbinectedin combined with pembrolizumab in relapsed small-cell #LungCancer (SCLC) patients who had not previously received immunotherapy. In this phase I/II, single-arm study, 28 patients were enrolled, with 50% being platinum-resistant. The objective response rate (ORR) was 46.4%, including three complete responses. The median duration of response (DoR) was 7.8 months, with 40% of patients maintaining responses for over 12 months. Platinum-sensitive patients had better progression-free survival (8.0 vs. 2.8 months) and numerically improved overall survival. Grade ≥3 treatment-related adverse events occurred in 71.4% of patients, with neutropenia being the most common. The combination demonstrated promising efficacy and a manageable safety profile, particularly for platinum-sensitive patients, warranting further investigation. Antonio Calles Alejandro Navarro ?Enric Alvarez Colomé María de Miguel ?Rosa Alvarez, MD ?Victor Moreno Pedro Rocha Emiliano Calvo Aller ?Elena Corral de la Fuente Daniel Alcalá López ?Olga Boix, PhD MELISSA FERNANDEZ PINTO ?Jose Rodríguez Morató, PhD Ramon Palmero Ernest Nadal Enriqueta Felip MEDSIR
-
-
The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. #ProstateCancer
Evaluation of Surgical Margins with Intraoperative PSMA PET/CT and Their Prognostic Value in Radical Prostatectomy https://lnkd.in/dKAFU3tx Study evaluated the accuracy of functional tumor-volume segmentation using intraoperative ex vivo PET/CT with [18F]PSMA-1007 for detecting positive resection margins in high-risk prostate cancer patients undergoing radical prostatectomy. Seven patients were included, and four semiautomatic segmentation methods were used to assess tumor margins, which were then compared to histopathology. PET/CT successfully analyzed 18 lesions, achieving 83% sensitivity, 100% specificity, and 100% positive predictive value for margin detection using iterative thresholding. One patient experienced biochemical recurrence within a year, while the others remained recurrence-free. A minimum activity concentration of 2 kBq/mL was determined for accurate segmentation, with proposed [18F]PSMA-1007 doses of 1.9 MBq/kg preoperatively and 0.4 MBq/kg intraoperatively. #ProstateCancer The results suggest intraoperative ex vivo PET/CT could be useful for margin assessment, though further trials are needed. Alexandros Moraitis,? Jens Kandziora David Kersting Henning Reis (MD, PD Dr. med.) Jens K?llermann Claudia Kesch,? Ulrich Krafft Boris Hadaschik Habib Zaidi, FIEEE, FAIMBE, FAAPM, FIOMP, FAAIA, FBIR Ken Herrmann Wolfgang Fendler Christopher Darr Pedro Fragoso Costa
-
-
OncoAlert转发了
In this episode of Your Stories, Dr. Stacy Loeb discusses the increasing spread of medical misinformation, its consequences, and how members of the cancer community can separate fact from falsehood. Listen now: https://lnkd.in/eeUfhJcK
-
The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients, though efficacy in ICI-treated patients was modest. The safety profile was consistent with known data for the combination. Metastatic Urothelial Carcinoma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts https://lnkd.in/drk2WncU The COSMIC-021 study investigated the safety and efficacy of cabozantinib plus atezolizumab in patients with advanced urothelial carcinoma (UC) across four cohorts: first-line cisplatin-eligible, cisplatin-ineligible, previously treated with platinum-based chemotherapy, and previously treated with immune checkpoint inhibitors (ICI). Patients received cabozantinib and atezolizumab, with the primary endpoint being objective response rate (ORR). Results showed ORRs of 30%, 20%, 27%, and 10% for the respective cohorts. Median progression-free survival ranged from 3.0 to 5.6 months. Grade 3/4 treatment-related adverse events occurred in up to 67% of patients, with no grade 5 events. The combination demonstrated clinical activity, particularly in cisplatin-eligible and chemotherapy-treated patients, though efficacy in ICI-treated patients was modest. The safety profile was consistent with known data for the combination. Sumanta Pal, MD, FASCO LORIOT Yohann Andrea Necchi Daniel Castellano Ulka Vaishampayan Ralph Hauke Thomas Powles,MD Carla Van Herpen Kevin Courtney Dreicer Robert Ramu Sudhagoni Martin Schwickart Neeraj Agarwal, MD, FASCO
-
-
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell #LungCancer ?? #NSCLC #CancerHasNoAge ?? https://lnkd.in/drURdT4s Study evaluated the impact of frailty and Karnofsky Performance Status (KPS) on outcomes in older adults (≥65) with advanced non-small cell lung cancer (aNSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy. A frailty index categorized patients as robust, pre-frail, or frail, and its associations with overall survival (OS), hospitalizations, functional decline, and toxicity were analyzed. Among 155 patients (median age 73), frail or pre-frail patients had significantly worse OS (hazard ratio 2.09), higher rates of hospitalization, functional decline, and grade ≥3 hematologic toxicity. KPS was only associated with OS. The findings suggest that pretreatment frailty assessments could guide decision-making and improve supportive care for older adults with aNSCLC. John Boscardin,?? Smith Giri, MD MHS? Grant Williams MD, MSPH, FASCO Carolyn J Presley, MD MHS,?? Li-Wen Huang,? Ana Velázquez Ma?ana, MD MSc FASCO (Velazquez Manana),?? Matthew Gubens, MD, MS, FASCO,?? Collin Blakely,?? Claire Mulvey,?? Michael L. Cheng, MD,? Lori Sakoda,? ?Larry Kushi,?? Charles Quesenberry,?? Sara Fleszar-Pavlovic,?? Anne Marie Mercurio Ping William Dale MD, PhD, FASCO Ishwaria Subbiah, MD, MS, FASCO Dr. Joseph McCollom DO Nicolò Matteo Luca Battisti Ravindran Kanesvaran Rowela "Leah" Mallare
-
-
The results suggest that SBRT may be a viable option for treating oligomestatatic CRPC after progression compared to systemic therapy. #ProstateCancer
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial https://lnkd.in/d3BVqPkK The ARTO trial, a phase II randomized study, evaluated the efficacy of combining Abiraterone acetate plus prednisone (AAP) with stereotactic body radiotherapy (SBRT) ??in patients with oligometastatic castration-resistant #ProstateCancer (omCRPC). This analysis focused on whether the benefit of SBRT persists after oligoprogression. After the first progression event, patients were divided into two groups: Group A, which received SBRT, and Group B, which received second-line systemic therapy. The study found no significant difference in progression-free survival (PFS) or overall survival (OS) between the two groups, though there was a non-significant trend favoring SBRT. The results suggest that SBRT may be a viable option for treating omCRPC after progression compared to systemic therapy. Giulio Francolini Vanessa Di Cataldo? Michele Aquilano alessio bruni Rolando M. D’Angelillo ?Luca Tagliaferri Matteo Augugliaro Silvana Parisi ?Giorgia Timon Giulia Marvaso Barbara Jereczek-Fossa ?Andrea Lancia Ciro Franzese Filippo Alongi Gabriele Simontacchi DANIELA GRETO Mauro Loi Luca Burchini Isacco Desideri ?Icro Meattini Richard Valicenti Lorenzo Livi
-
-
FREE WEBINAR on HER2??testing & evolving role of IHC?? in #LungCancer & #OvarianCancer REGISTER HERE ?? https://buff.ly/PKNFKVP JOIN US TUESDAY MARCH 11, 2025 This LIVE Event is chaired by Prof. Fernando Lopez-Rios with co-chairs Prof. Charlie Gourley and OncoAlert Faculty Christian Rolfo, MD, PhD, MBA,Dr.hc . Topics include challenges, best practices, HER2 immunohistochemistry interpretation, expert insights, cases, and Q&A. COR2ED
-